We are live on ! Find out more
MRUS

Merus

Delisted

MRUS was delisted on the 29th of December, 2025.

10 hedge funds and large institutions have $5.73M invested in Merus in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 257 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $1.37M | Put options by funds: $1.06M

93.93% less ownership

Funds ownership: 94.05%0.12% (-94%)

96% less funds holding

Funds holding: 26810 (-258)

99% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 257

100% less capital invested

Capital invested by funds: $6.69B → $5.73M (-$6.69B)

100% less funds holding in top 10

Funds holding in top 10: 330 (-33)

Holders
10
Holders Change
-258
Holders Change %
-96.27%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
-33
Holding in Top 10 Change %
-100%
% of All Funds
New
3
Increased
3
Reduced
Closed
257
Calls
$1.37M
Puts
$1.06M
Net Calls
+$306K
Net Calls Change
-$86.4M

MRUS Hedge Fund Activity: Q4 2025 in Review

10 institutional investors reported a position in Merus (MRUS) for Q4 2025, worth a combined $5.73M — down 100% from $6.69B a quarter earlier.

Sellers outnumbered buyers: 257 funds closed out of MRUS and 3 opened new positions — a net loss of 254 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was XTX Topco, adding an estimated $1.42M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $412M sold.

  • 10 institutional investors held Merus (MRUS) as of Q4 2025, down from 268 in Q3 2025.
  • Funds reported $5.73M of Merus stock for Q4 2025, down 100% quarter-over-quarter.
  • 3 funds opened new Merus positions in Q4 2025 and 257 closed out, a net change of -254 holders.
  • The largest Merus buyer in Q4 2025 was XTX Topco, an estimated $1.42M added.
  • The largest Merus seller in Q4 2025 was Paradigm Biocapital Advisors, an estimated $412M sold.

Based on aggregated 13F filings for Q4 2025.